Literature DB >> 30405808

Evaluation of positive ductal margins of biliary tract cancer in intraoperative histological examination.

Junji Ueda1,2, Hiroshi Yoshida2, Yasuhiro Mamada1, Nobuhiko Taniai1, Masato Yoshioka1, Atsushi Hirakata2, Youichi Kawano1, Yoshiaki Mizuguchi1, Tetsuya Shimizu1, Tomohiro Kanda1, Hideyuki Takata2, Ryota Kondo1, Eiji Uchida1.   

Abstract

At present the only method available to confirm microscopic infiltration of cancer into ductal margins during surgery, is intraoperative histological examination. In the present study, the status of the surgical margins and postoperative course were evaluated to determine any correlation between remnant carcinoma and postoperative survival. All consecutive patients who underwent resection for biliary tract cancer between January 2004 and May 2012 were identified from a database. Positive margin cases were divided into two groups, invasive carcinoma and carcinoma in situ (CIS). Immunohistochemical staining targeting Ki67 and p53 for positive margins was performed. Cases of major vessel invasion were significantly increased in the positive group compared with the negative group. The recurrence rate was significantly lower in the CIS group compared with the invasive group. The survival rate was significantly increased in the CIS group compared with the invasive group. The expression levels of p53 and Ki67 were significantly increased in the invasive group compared with the CIS group. No statistical correlations were observed between the expression of p53 or Ki67 and the survival or recurrence of disease. In the positive group, resected margin status was the principal factor associated with recurrence-free survival according to Cox-regression analysis. In conclusion, the status of the resected margins in the positive group was the most important factor for postoperative survival and recurrence in cholangiocarcinoma, not immunohistochemical staining targeting Ki67 and p53.

Entities:  

Keywords:  cholangiocarcinoma; intraoperative histological examination; surgery

Year:  2018        PMID: 30405808      PMCID: PMC6202532          DOI: 10.3892/ol.2018.9479

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  43 in total

1.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

2.  A new histological classification for intra-operative histological examination of the ductal resection margin in cholangiocarcinoma.

Authors:  Masaru Konishi; Atsushi Ochiai; Hidenori Ojima; Takahiro Hasebe; Masayuki Mano; Tamaki Ohta; Ichiro Ito; Keiko Sasaki; Satoru Yasukawa; Kazuaki Shimada; Motoki Iwasaki; Akio Yanagisawa
Journal:  Cancer Sci       Date:  2009-02       Impact factor: 6.716

3.  Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma.

Authors:  Yi-Yin Jan; Ta-Sen Yeh; Jun-Nan Yeh; Horng-Ren Yang; Miin-Fu Chen
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

Review 4.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

5.  Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma.

Authors:  Yoko Matsuda; Tetsushi Yamamoto; Mitsuhiro Kudo; Kiyoko Kawahara; Masashi Kawamoto; Yuki Nakajima; Kiyoshi Koizumi; Nando Nakazawa; Toshiyuki Ishiwata; Zenya Naito
Journal:  Int J Oncol       Date:  2008-12       Impact factor: 5.650

6.  Study of the intrahepatic surgical margin of hilar bile duct carcinoma.

Authors:  Yasunaga Okazaki; Tadashi Horimi; Masahito Kotaka; Sojiro Morita; Motohiro Takasaki
Journal:  Hepatogastroenterology       Date:  2002 May-Jun

7.  Impact of residual in situ carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma.

Authors:  Yoshitsugu Nakanishi; Satoshi Kondo; Yoh Zen; Atsuya Yonemori; Kanako Kubota; Hiroshi Kawakami; Eiichi Tanaka; Satoshi Hirano; Tomoo Itoh; Yasuni Nakanuma
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-06-12       Impact factor: 7.027

8.  An immunohistochemical study of p53 protein in gallbladder and extrahepatic bile duct/ampullary carcinomas.

Authors:  M Teh; A Wee; G C Raju
Journal:  Cancer       Date:  1994-09-01       Impact factor: 6.860

9.  Ki-67 detects a nuclear matrix-associated proliferation-related antigen. I. Intracellular localization during interphase.

Authors:  R Verheijen; H J Kuijpers; R O Schlingemann; A L Boehmer; R van Driel; G J Brakenhoff; F C Ramaekers
Journal:  J Cell Sci       Date:  1989-01       Impact factor: 5.285

10.  Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.

Authors:  Alexander R Siebenhüner; Heike Seifert; Helga Bachmann; Burkhardt Seifert; Thomas Winder; Jonas Feilchenfeldt; Stefan Breitenstein; Pierre-Alain Clavien; Roger Stupp; Alexander Knuth; Bernhard Pestalozzi; Panagiotis Samaras
Journal:  BMC Cancer       Date:  2018-01-11       Impact factor: 4.430

View more
  2 in total

1.  Significance of dysplasia in bile duct resection margin in patients with extrahepatic cholangiocarcinoma: A retrospective analysis.

Authors:  Jung Wan Choe; Hyo Jung Kim; Jae Seon Kim
Journal:  World J Clin Cases       Date:  2022-04-06       Impact factor: 1.534

Review 2.  Does high-grade dysplasia/carcinoma in situ of the biliary duct margin affect the prognosis of extrahepatic cholangiocarcinoma? A meta-analysis.

Authors:  Qiao Ke; Bin Wang; Nanping Lin; Lei Wang; Jingfeng Liu
Journal:  World J Surg Oncol       Date:  2019-12-09       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.